INTERIM REPORT JANUARY-SEPTEMBER 2015

THE JANUARY-SEPTEMBER PERIOD 2015 IN BRIEF

  · Net sales amounted to MSEK 11.7 (22.0), whereof the third quarter MSEK 9.4
(8.8)
  · Net loss was MSEK 53.5 (37.5), whereof the third quarter MSEK 16.6 (9.9)
  · Loss per share was SEK 1.14 (1.01), whereof the third quarter SEK 0.35
(0.27)
  · Cash flow from operating activities was MSEK -46.7 (-35.7), whereof the
third quarter MSEK -14.3 (-9.4)
  · Cash and cash equivalents and other short-term investments at the end of the
period totaled MSEK 132.1 (62.3)
  · Acquisition of the companies Apropharm AS and DNE Sverige AB

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

  · Acquisition of Swereco Group. The company has an annual turnover exceeding
MSEK 150. Swereco markets products to pharmacies and directly to healthcare
providers
  · Acquisition of MedCore AB. The company has an annual turnover of approx.
MSEK 50. MedCore markets primarily licensed medtech products to pharmacies and
hospitals in the Nordic region.

CONFERENCE CALL / AUDIOCAST TODAY AT 10.00 A.M. CET

A presentation of the report (in Swedish) will take place today 10.00 a.m. The
presentation and slides will be available through the corporate website
www.karobio.se or by telephone +46 8 566 426 69. Questions may be submitted over
the internet or by telephone.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Henrik Palm, CFO, +46 8 608 6076, +46 70 540 4014 or henrik.palm@karobio.se

ABOUT KARO BIO
Karo Bio is a healthcare company that develops and markets products to
pharmacies and directly to healthcare providers. The share is listed on Nasdaq
Stockholm.
The information in this report is such that Karo Bio is required to disclose
under the Swedish Securities Market Act. The information was disclosed on
October 29, 2015 at 8.30 a.m. CET.